All of our investigational products are independently developed and we possess the global rights. We are open to discussions with both oversea and domestic pharmaceutical and biotechnology companies on mutually beneficial cooperation, including out-licensing and co-development.
We are willing to explore potential cooperation in drug combination. The combination our assets with other immuno-oncology therapy, targeted drugs, and chemotherapy are all within the scope of discussion.
For Business Development, please Contact: +86(21)-53391528
Email: BD@wigenbio.com
